A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models
✍ Scribed by Ki Young Shin; Geon Ho Lee; Cheol Hyoung Park; Hee Jin Kim; Soo-Hyun Park; Seonghan Kim; Hye-Sun Kim; Kwan-Sun Lee; Beom Young Won; Hyung Gun Lee; Jin-Ho Choi; Yoo-Hun Suh
- Book ID
- 102908724
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 505 KB
- Volume
- 85
- Category
- Article
- ISSN
- 0360-4012
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p‐coumarate by the esterification of maltol and p‐coumaric acid. In the present study, we investigated whether maltolyl p‐coumarate could improve cognitive decline in scopolamine‐injected rats and in amyloid beta peptide~1–42~‐infused rats. Maltolyl p‐coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide~1–42~‐infused rats. We also examined the neuroprotective effects of maltolyl p‐coumarate in vitro using SH‐SY5Y cells. Cells were pretreated with maltolyl p‐coumarate, before exposed to amyloid beta peptide~1–42~, glutamate or H~2~O~2~. We found that maltolyl p‐coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p‐coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function. © 2007 Wiley‐Liss, Inc.